Fairvalue-Calculator Fairvalue-Calculator
EN DE

Active Biotech AB (ACTI) Fair Value & Analysis

Healthcare · SE · Market cap 177M SEK

Pricekr 5.62
Fair Valuekr 9.49
Upside+68.9%
Quality95/100
Evidence: Low Range kr 7.12 – kr 11.86

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Active Biotech AB (ACTI) currently trades at kr 5.62, while our model-based Fair Value estimate is kr 9.49 — implying the stock looks roughly 68.9% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas and Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Active Biotech AB (ACTI) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 9.49 versus a price of kr 5.62 — about +69% (undervalued). Model-based estimate, not financial advice.
What is the fair value of ACTI?
Our 21-model fair value for Active Biotech AB is kr 9.49 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 5.62.
What is the quality score of ACTI?
Active Biotech AB has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.